Document is current
Any future updates will be listed below
-
Authors
Polyzoi, Maria
Ekman, Mattias
Reithmeier, Anja
Jacob, Johanna
Karlsson, Emma
Bertranou, Evelina
Linderholm, Barbro
Hettle, Robert https://orcid.org/0000-0002-1100-1266
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Accepted: 19 November 2023
First Online: 13 December 2023
Declarations
:
: This study was funded by AstraZeneca.
: MP, ME, AR, JJ, EK, EB and RH are employees and stockholders of AstraZeneca. BL has received honoraria for advisory boards and providing expert input on this economic analysis from AstraZeneca, as well as honoraria for various activities from Daiichi-Sankyo, Pfizer, Eli Lilly, Novartis, Gilead, Seagen and Merck.
: Not applicable.
: Not applicable.
: Not applicable.
: Model inputs are described in the manuscript, electronic supplementary material, and references. No further data and material are available.
: Not available.
: All authors contributed to the design of the study, were involved in drafting the outline, first, and second drafts, and approved the final version of the manuscript. RH is guarantor of this manuscript.
: Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data-sharing policy, described at: .
